Zur Rose Group AG
A European e-commerce pharmacy providing an online platform for medicines and health.
ROSE | SW
Overview
Corporate Details
- ISIN(s):
- CH0042615283 (+1 more)
- LEI:
- 50670038OH136R5Z4663
- Country:
- Switzerland
- Address:
- Walzmühlestrasse 49, 8500 Frauenfeld
- Sector:
- Wholesale and retail trade
Description
DocMorris AG, formerly Zur Rose Group AG, is a leading European e-commerce pharmacy. The company provides an online platform for medicines and develops digital health services. Its core strategy involves creating a comprehensive digital health ecosystem that connects patients, doctors, pharmacies, and health insurers on a single platform. The company's vision is to enable individuals to manage their health with a single click, offering integrated care and treatment solutions. Originally founded as a pharmacy wholesaler, it has evolved to focus on the digitalization of healthcare services.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-01 07:00 |
Zur Rose Group successfully completes placement of approx. CHF 95 million Conve…
|
English | 3.8 KB | ||
| 2022-09-01 02:00 |
Zur Rose Group successfully completes placement of approx. CHF 95 million Conve…
|
English | 2.4 KB | ||
| 2022-09-01 02:00 |
Zur Rose Group schliesst Platzierung einer etwa CHF 95 Mio. Wandelanleihe und d…
|
German | 2.7 KB | ||
| 2022-08-31 17:41 |
Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. C…
|
English | 4.2 KB | ||
| 2022-08-31 02:00 |
Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. C…
|
English | 2.6 KB | ||
| 2022-08-31 02:00 |
Zur Rose Group lanciert Platzierung einer Wandelanleihe mit Gesamtnennbetrag vo…
|
German | 2.7 KB | ||
| 2022-08-18 07:00 |
Zur Rose Group speeds up path to profitability and plans break-even at EBITDA l…
|
English | 30.7 KB | ||
| 2022-08-18 02:00 |
Zur Rose Group speeds up path to profitability and plans break-even at EBITDA l…
|
English | 25.8 KB | ||
| 2022-08-18 02:00 |
Zur Rose-Gruppe beschleunigt Weg zur Profitabilität mit geplantem EBITDA-Break-…
|
German | 27.0 KB | ||
| 2022-08-18 00:00 |
Presentation on Half-Year Results 2022
|
English | 2.4 MB | ||
| 2022-08-18 00:00 |
Präsentation zum Halbjahresergebnis 2022
|
German | 2.4 MB | ||
| 2022-08-18 00:00 |
Half-Year Report 2022
|
English | 142.3 KB | ||
| 2022-08-18 00:00 |
Halbjahresbericht 2022
|
German | 153.6 KB | ||
| 2022-08-08 00:00 |
Halbjahresergebnis-Präsentation 2022
|
English | 2.4 MB | ||
| 2022-06-17 14:32 |
Tobias Leipold, CEO und Co-Founder, verlasst die eHealth-Tec GmbH
|
German | 7.0 KB |
Automate Your Workflow. Get a real-time feed of all Zur Rose Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Zur Rose Group AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Zur Rose Group AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-20 | N/A | Non-Executive member | Buy | None | 175,188.00 CHF |
| 2025-05-20 | N/A | Non-Executive member | Buy | None | 28,818.00 CHF |
| 2025-05-19 | N/A | Executive member | Buy | None | 34,500.00 CHF |
| 2025-05-19 | N/A | Non-Executive member | Buy | None | 14,040.00 CHF |
| 2025-05-19 | N/A | Executive member | Buy | None | 9,142.50 CHF |
| 2025-05-16 | N/A | Non-Executive member | Buy | None | 1,035,000.00 CHF |
| 2025-05-16 | N/A | Executive member | Buy | None | 46,400.00 CHF |
| 2025-05-16 | N/A | Executive member | Buy | None | 10,315.50 CHF |
| 2025-05-16 | N/A | Non-Executive member | Buy | None | 8,616.00 CHF |
| 2025-05-15 | N/A | Executive member | Buy | None | 678,770.25 CHF |
Peer Companies
